At this year’s ASCO annual meeting, CRC management insights were revealed in several abstract presentations covering pembrolizumab, regorafenib, immunotherapies, trifluridine/tipiracil plus bevacizumab, and an antibody-drug conjugate targeting HER2.
It is important for young people, caregivers, and healthcare providers to recognize possible symptoms of colorectal cancer (CRC) and arrange a colonoscopy or other tests when necessary. This article presents a thorough review of CRC and its impact on young patients, including a hypothesis for the increase of cases, screening recommendations, demographic features, symptoms, and […]
The third case in a three-part series, this article chronicles the treatment journey of a 50-year-old male patient who had been diagnosed with left-sided colon cancer in January 2016. After multiple FOLFOX doses, FOLFIRI cycles, and resection, the patient began treatment with regorafenib in July 2020 as a third-line treatment, with the hope that this […]
The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy.
According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.
The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.
In this Original Investigation from JAMA Oncology, the authors attempt to discover whether increased coffee consumption is associated with improved survival in patients with advanced or metastatic colorectal cancer. Overall survival (OS) and progression-free survival (PFS) were the main outcomes and measures, and both decaffeinated and caffeinated coffee were studied.